Cantor Fitzgerald Lifts Earnings Estimates for Omeros

Omeros Corporation (NASDAQ:OMER) – Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings estimates for Omeros in a research report issued to clients and investors on Monday, August 18th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will earn ($1.69) per share for the year, up from their prior estimate of ($2.14). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros’ FY2026 earnings at ($0.97) EPS.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02. The company had revenue of $28.60 million for the quarter, compared to analyst estimates of $0.31 million.

Several other research firms have also issued reports on OMER. D. Boral Capital reissued a “buy” rating and issued a $36.00 price target on shares of Omeros in a research report on Friday, August 15th. Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 27th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Omeros in a research report on Friday, June 27th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Omeros Stock Down 3.9%

NASDAQ:OMER opened at $4.19 on Wednesday. Omeros has a 12-month low of $2.95 and a 12-month high of $13.60. The firm has a market capitalization of $285.17 million, a PE ratio of -1.99 and a beta of 2.26. The firm has a 50-day moving average price of $3.62 and a 200 day moving average price of $5.70.

Institutional Trading of Omeros

Several hedge funds have recently modified their holdings of OMER. Nomura Holdings Inc. grew its stake in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Omeros during the fourth quarter valued at approximately $1,488,000. Wellington Management Group LLP bought a new stake in shares of Omeros during the first quarter valued at approximately $1,118,000. Nuveen LLC bought a new stake in shares of Omeros during the first quarter valued at approximately $938,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Omeros during the second quarter valued at approximately $316,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.